title: Twenty-year durability of the aortic Hancock II bioprosthesis in young patients: is it durable enough?.
abstract: OBJECTIVE
  There is a current trend towards the use of bioprosthetic aortic valves in the aortic position in young patients, but there is limited information on durability beyond the first decade. The Hancock II bioprosthesis has been reported to have excellent durability in patients ≥ 60 years of age. This study examines the long-term durability of the Hancock II bioprosthesis in the aortic position in patients <60 years of age.
  
  
  METHODS
  From 1982 to 2008, 304 patients aged 59 years or less underwent aortic valve replacement (AVR) with a Hancock II bioprosthesis at two centres. The mean age was 49.2 ± 9.0 years, and 79% of the patients were male. Valve function was serially assessed by echocardiography. The median follow-up was 14.6 years (maximum 27.5 years). Survival and freedom from adverse events were calculated by using a Kaplan-Meier method. Independent predictors of those events were assessed by using Cox proportional hazards analyses.
  
  
  RESULTS
  Survival and freedom from repeat AVR (re-AVR) at 20 years were 57.0 ± 6.1 and 25.4 ± 4.7%, respectively. During the follow-up, 100 patients (33%) underwent re-AVR: 78 for structural valve deterioration (SVD), 11 for endocarditis, 4 for non-structural valve dysfunction and 7 for other reasons. The overall 10-, 15- and 20-year freedom from re-AVR due to SVD were 91.4 ± 2.1, 64.7 ± 4.3 and 29.1 ± 5.3%, respectively. By age group, the 20-year freedom from re-AVR due to SVD amounted to 14.1 ± 8.7% in patients younger than 40 years of age, 21.5 ± 8.5% in patients aged 40-49 and 41.4 ± 8.2% in patients between 50 and 59 (P = 0.04). The independent predictors of re-AVR due to SVD were age [odds ratio (OR): 0.72 per 10 years; 95% confidence interval (CI): 0.58, 0.90; P < 0.01] and prosthesis-patient mismatch (PPM) (effective orifice area index <0.80 cm(2)/m(2)) (OR: 1.63; 95% CI: 1.01, 2.63; P = 0.045).
  
  
  CONCLUSIONS
  The Hancock II bioprosthesis for AVR in patients <60 years of age is associated with excellent durability during the first decade. However, SVD increases dramatically during the second decade and by 20 years, especially in patients aged <50 and/or with PPM. These findings may assist prosthesis selection for patients and their surgeons.
authors: Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, ON, Canada.
authors: Dai
authors: D
authors: Une
authors: Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, ON, Canada.
authors: Marc
authors: M
authors: Ruel
authors: Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Toronto, ON, Canada tirone.david@uhn.on.ca.
authors: Tirone E
authors: TE
authors: David
mesh_terms: D000328:Adult; D001021:Aortic Valve / Q000601:surgery*; D001705:Bioprosthesis / Q000009:adverse effects / Q000592:standards*; D005260:Female; D006350:Heart Valve Prosthesis / Q000009:adverse effects / Q000592:standards*; D019918:Heart Valve Prosthesis Implantation / Q000295:instrumentation* / Q000379:methods / Q000592:standards; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology; D011475:Prosthesis Failure; D012086:Reoperation; D012189:Retrospective Studies; D013923:Thromboembolism
keywords: Aortic valve; Bioprosthesis; Prosthesis durability